AbbVie

News

Shares in AbbVie were lifted today after the company revealed that it has settled patent litigation with generic drugmakers on blockbuster Rinvoq.

News

Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.

News

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

News

AbbVie has filed for FDA approval of a new front-line therapy for chronic lymphocytic leukaemia that it thinks could be 'practice changing."

News

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo

News

AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.